How Long Does 30 mg Isosorbide Mononitrate Stay in Your System?
Isosorbide mononitrate (ISMN) has a half-life of approximately 4 to 5 hours, meaning a 30 mg dose is substantially eliminated from your body within 20-25 hours (about 5 half-lives), though detectable effects may persist for 12-17 hours after a single dose.
Pharmacokinetic Profile
The elimination of isosorbide mononitrate follows a predictable pattern 1:
- Half-life: 4 to 5 hours 2
- Time to peak concentration: 30-60 minutes after immediate-release formulation 2
- Bioavailability: Approximately 100% (no first-pass metabolism) 2, 3
- Volume of distribution: 0.6 to 0.7 L/kg 2
- Protein binding: Only 5% 2
Duration in Your System
Complete elimination timeline:
- After 5 hours: ~50% remains
- After 10 hours: ~25% remains
- After 15 hours: ~12.5% remains
- After 20-25 hours: <5% remains (essentially eliminated)
The drug is primarily metabolized by the liver through denitration and glucuronidation, with 96% excreted in urine within 5 days and only about 1% eliminated in feces 2. Only 1-2% is excreted unchanged 3.
Clinical Duration of Effect
The pharmacological effects last considerably shorter than complete elimination 4, 5, 4, 6:
- Immediate-release formulations: Effects last 12-24 hours depending on dose 4
- Extended-release formulations: Antianginal effects demonstrated for up to 12-17 hours 2, 7, 8
- Onset of action: 30 minutes 7, 8
For the extended-release 30 mg dose specifically, clinical studies show continued improvement in exercise performance at 4 and 12 hours after dosing 2.
Important Clinical Considerations
Drug interactions requiring specific timing:
The most critical interaction involves phosphodiesterase-5 (PDE5) inhibitors 4, 5, 4, 6, 9, 10:
- Sildenafil or vardenafil: Avoid nitrates for at least 24 hours
- Tadalafil: Avoid nitrates for at least 48 hours
- Avanafil: Avoid nitrates for at least 12 hours 9
These combinations can cause profound, potentially fatal hypotension because PDE5 inhibitors markedly exaggerate and prolong nitrate-mediated vasodilation 4, 5, 4, 6.
Special Populations
The pharmacokinetics remain consistent across different patient groups 2:
- Elderly patients (≥65 years): No significant differences in elimination
- Renal insufficiency: No prolonged half-life or drug accumulation
- Liver cirrhosis: Similar disposition to healthy subjects
- Cardiac dysfunction: No altered pharmacokinetics
However, elderly patients receiving higher doses (120 mg) showed 30% lower apparent oral clearance, though this was not statistically significant 2.
Practical Implications
For once-daily dosing regimens, the drug is designed to provide therapeutic effects throughout the day while allowing a nitrate-free interval overnight to prevent tolerance 1. This dosing strategy maintains efficacy without the development of tolerance that occurs with continuous 24-hour exposure 2.
If you need to know when the drug is completely out of your system (for example, before taking a PDE5 inhibitor or undergoing certain procedures), waiting 24 hours after your last dose ensures virtually complete elimination, though the critical drug interaction window is specifically defined by the PDE5 inhibitor half-life rather than the nitrate half-life.